SIM Acquisition Corp. I (SIMAW) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 48.51 means the share price is 48.51 times one year of earnings per share.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSIM Acquisition Corp. I (SIMAW) trades at $0.15. SIM Acquisition Corp. I is a shell company established in 2024, focused on executing a strategic business combination within the healthcare industry. Sector: Financials.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for SIMAW: SIMAW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
SIM Acquisition Corp. I (SIMAW) Financial Services Profile
SIM Acquisition Corp. I, established in 2024 and based in Miami, Florida, operates as a shell company focused on identifying and completing a strategic business combination within the healthcare industry. As a subsidiary of SIM Sponsor 1 LLC, its primary objective is to merge with or acquire one or more healthcare entities to create long-term value for shareholders.
What Is the Investment Thesis for SIMAW?
SIM Acquisition Corp. I presents an investment thesis centered on its potential to execute a value-accretive business combination within the high-growth healthcare sector. The company's strategic focus on healthcare, a sector characterized by innovation, demographic tailwinds, and consistent demand, positions it to potentially merge with or acquire a promising entity. The backing of SIM Sponsor 1 LLC suggests a structured approach to deal sourcing and due diligence, which is critical for successful transactions in this space. While SIMAW currently lacks operational assets, its market capitalization of $0.01 billion and P/E ratio of 48.51 reflect the market's anticipation of a future combination. The successful completion of a merger or acquisition could unlock significant value by providing a private healthcare company with public market access and growth capital, potentially leading to a re-rating of the combined entity. Key catalysts include the announcement of a definitive agreement with a target company and the subsequent closing of the business combination, which would transition SIMAW from a shell company to an operating entity with tangible assets and revenue streams.
Based on FMP financials and quantitative analysis
SIMAW Key Highlights
Market Capitalization stands at $0.01 billion, reflecting its current status as a shell company awaiting a business combination.
- Price-to-Earnings (P/E) ratio is 29.14, indicating market expectations for future earnings growth post-acquisition, despite current minimal operations.
- Beta of -0.01 suggests an inverse and highly uncorrelated relationship with the broader market, typical for a non-operating shell entity.
- Established in 2024, the company is a relatively new entrant, signifying its recent formation to pursue a strategic healthcare acquisition.
- Operates with a lean team of 2 employees, underscoring its non-operational nature and focus solely on facilitating a business combination.
Who Are SIMAW's Competitors?
SIMAW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| UMAC UMAC | $21.88 | -2.12% | $1.07B | 30 5-pillar |
| DMII Drugs Made In America Acquisition II Corp. | $10.19 | +0.05% | $648M | 54 5-pillar |
| BCSS Bain Capital GSS Investment Cor | $10.22 | -0.10% | $479M | 52 5-pillar |
| CEPF Cantor Equity Partners IV, Inc. | $10.27 | -0.19% | $472M | 51 5-pillar |
| KFII K&F Growth Acquisition Corp. II Class A Ordinary shares | $10.71 | +0.09% | $420M | 50 5-pillar |
| AAC Ares Acquisition Corporation | $10.05 | -0.10% | $397M | 51 5-pillar |
| TACO Berto Acquisition Corp. | $10.46 | 0.00% | $392M | 52 5-pillar |
| RDAG Republic Digital Acquisition Company | $10.45 | -0.10% | $392M | 49 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SIMAW's Key Strengths?
Dedicated focus on the high-growth healthcare industry.
- Backed by SIM Sponsor 1 LLC, potentially providing expertise and network.
- Lean operational structure with minimal overhead.
- Provides an alternative, potentially faster, route to public markets for private companies.
What Are SIMAW's Weaknesses?
Lacks substantial business activities or revenue-generating operations.
- Success is entirely dependent on the ability to complete a business combination.
- Small team of 2 employees limits internal resources for extensive due diligence without external support.
- Relatively new entity (established 2024) may have less established track record than older SPACs.
What Are the Key Risks for SIMAW?
Financial-distress signal — its Altman Z-Score of 1.47 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Rich valuation — a P/E of 48.51 runs well above the Financial Services sector’s ~17.20x, leaving little room for a miss.
- Failure to identify and complete a suitable business combination within a reasonable timeframe, which could lead to the company's liquidation.
- Intense competition from other special purpose acquisition companies and private equity firms for attractive healthcare acquisition targets.
- Market volatility and economic downturns could negatively impact investor sentiment and the valuation of potential target companies.
- Regulatory hurdles or changes in the healthcare industry that could complicate or delay a proposed business combination.
- Dependence on the expertise and network of SIM Sponsor 1 LLC for deal sourcing and execution, introducing reliance risk.
What Are SIMAW's Competitive Advantages?
- Strategic focus on the healthcare industry, a sector with strong growth fundamentals.
- Potential access to a network of private healthcare companies through SIM Sponsor 1 LLC.
- Ability to offer a streamlined path to public markets for private companies.
- Lean operational structure, minimizing overhead costs prior to a business combination.
What Does SIMAW Do?
SIM Acquisition Corp. I, founded in 2024 and headquartered in Miami, Florida, functions as a specialized shell company with a singular, well-defined objective: to complete a strategic business combination. Unlike traditional operating companies, SIM Acquisition Corp. I currently lacks substantial business activities or revenue-generating operations. Its entire corporate structure and strategic focus are geared towards identifying, evaluating, and ultimately consummating a significant transaction, such as a merger, stock swap, asset takeover, equity purchase, or a comparable corporate restructuring. This strategic consolidation is specifically targeted at one or more entities operating within the dynamic and expansive healthcare industry. As a subsidiary of SIM Sponsor 1 LLC, the company benefits from the backing and potential expertise of its parent entity, which likely plays a crucial role in deal sourcing, due diligence, and transaction execution. The establishment in 2024 positions it as a relatively new entrant in the landscape of special purpose acquisition vehicles, aiming to leverage market opportunities within healthcare. Its operational footprint is minimal, with a lean team of two employees, reflecting its non-operational nature prior to a business combination. The company's evolution is entirely predicated on the successful execution of this core objective, transforming from a shell entity into a combined operating business within the healthcare sector, thereby offering a pathway for a private healthcare company to access public markets.
What Products and Services Does SIMAW Offer?
- Operates as a shell company with no active business operations.
- Seeks to identify and acquire one or more businesses in the healthcare industry.
- Aims to complete a strategic consolidation, such as a merger or stock swap.
- Functions as a vehicle for a private healthcare company to become publicly traded.
- Leverages the backing and potential expertise of its parent, SIM Sponsor 1 LLC.
- Established in 2024, focusing on a single, transformative transaction.
- Headquartered in Miami, Florida, with a lean operational team.
How Does SIMAW Make Money?
- Raise capital through the issuance of securities (implied by its nature as a shell company, though not explicitly stated in sources).
- Utilize raised capital to acquire or merge with a private operating company in the healthcare sector.
- Generate value for shareholders through the successful execution of a business combination, transforming into an operating entity.
- Benefit from the sponsor's network and expertise to source and vet potential target companies.
What Industry Does SIMAW Operate In?
SIM Acquisition Corp. I operates within the 'Shell Companies' industry, a segment of the broader Financial Services sector. This industry is primarily composed of Special Purpose Acquisition Companies (SPACs) and similar blank-check firms whose sole purpose is to raise capital through an initial public offering (IPO) and then use those funds to acquire an existing private company. The market for shell companies is influenced by overall capital market liquidity, investor appetite for risk, and the availability of suitable private companies seeking public market access. While the SPAC market has experienced periods of heightened activity and subsequent cooling, the underlying demand for efficient pathways to public markets persists. SIM Acquisition Corp. I differentiates itself by explicitly targeting the healthcare industry, a sector known for its resilience, innovation, and long-term growth drivers. Its competitive landscape includes other SPACs and shell companies, as well as traditional private equity firms and venture capitalists, all vying for attractive private healthcare assets. The company's success is intrinsically tied to its ability to identify and secure a high-quality target within this competitive environment.
Who Are SIMAW's Key Customers?
- Primary 'customer' is the private healthcare company seeking to go public via a business combination.
- Investors who purchase SIMAW's securities, anticipating value creation from a future merger.
- Potential strategic partners within the healthcare industry for future collaborations post-combination.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is a warrant, not an operating company
MoonshotScore History
Recorded daily since 2026-08-23 · 43 snapshots
| 2026-08-23 | 48 |
| 2026-08-31 | 48 |
| 2026-09-08 | 48 |
| 2026-09-16 | 48 |
| 2026-09-24 | 48 |
| 2026-10-04 | 48 |
| 2026-10-06 | 48 |
What changed?
The score has stayed at 48.
Over the same 30 days the stock moved -11.8%.
Financial Health
SIM Acquisition Corp. I's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.47 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for SIM Acquisition Corp. I stands at 3.7%, a gauge of how efficiently it converts shareholder capital into profit. SIMAW trades at a trailing price-to-earnings ratio of 48.51, above the Financial Services sector average of ~17.20x. Its free cash flow yield is -0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.30 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 6.2%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
SIM Acquisition Corp. I operates in the Shell Companies industry within the Financial Services sector. It is headquartered in New York, US. The company is led by CEO Christopher Devall. SIMAW has traded publicly since 2024.
Insider Activity
2 transactions · 0 purchases, 0 sales, 2 other transactions · 1 identified insiders · available records within the last 180 days, newest dated May 11, 2026 (coverage not recorded). Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
SIMAW Financials
Bull Case vs Bear Case
Bull Case
- Dedicated focus on the high-growth healthcare industry.
- Backed by SIM Sponsor 1 LLC, potentially providing expertise and network.
- Lean operational structure with minimal overhead.
- Provides an alternative, potentially faster, route to public markets for private companies.
Bear Case
- Lacks substantial business activities or revenue-generating operations.
- Success is entirely dependent on the ability to complete a business combination.
- Small team of 2 employees limits internal resources for extensive due diligence without external support.
- Relatively new entity (established 2024) may have less established track record than older SPACs.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026
SIMAW Latest News
No recent news available for SIMAW.
SIMAW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SIMAW.
Price Targets
Wall Street price target analysis for SIMAW.
SIMAW MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SIMAW; grades run from A+ (80-100) to F (below 30).
Leadership: Christopher Devall
Chief Executive Officer
Christopher Devall serves as the Chief Executive Officer of SIM Acquisition Corp. I. His role involves overseeing the strategic direction and operational execution of the company's primary objective: to identify and complete a business combination. Given the company's focus on the healthcare industry, Mr. Devall's background likely includes experience in corporate finance, mergers and acquisitions, or the healthcare sector itself, which would be critical for navigating complex transactions and identifying suitable target companies. His leadership is central to the company's efforts to transition from a shell entity to an operating business.
Track Record: Under Christopher Devall's leadership, SIM Acquisition Corp. I has been established in 2024 with a clear mandate to pursue a strategic business combination in the healthcare sector. His primary achievement to date involves setting up the corporate framework and guiding the initial phases of target identification. With a lean team of two employees, Mr. Devall is responsible for driving the company's efforts to secure a transformative merger or acquisition, which will define its future operational trajectory and value creation for shareholders.
SIM Acquisition Corp. I Financials Stock: Key Questions Answered
What is the typical timeline for SIM Acquisition Corp. I to complete a business combination?
For shell companies like SIM Acquisition Corp. I, the timeline for completing a business combination typically ranges from 18 to 24 months from their initial public offering or establishment, though this specific company's IPO date is not provided. Since SIM Acquisition Corp. I was incorporated in 2024, it is actively within this period.
What is the strategic rationale behind SIM Acquisition Corp. I targeting the healthcare industry?
SIM Acquisition Corp. I's strategic focus on the healthcare industry is driven by the sector's robust and enduring growth fundamentals.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Growth opportunities, investment thesis, and risks are based on the typical operational model of a shell company focused on a specific industry, extrapolated from the provided core business description.